EP 1622875 B1 20091202 - CRYSTALLINE FORMS OF AN ARYLANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST
Title (en)
CRYSTALLINE FORMS OF AN ARYLANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST
Title (de)
KRISTALLINE FORMEN EINES ARYLANILIN-BETA-2-ADRENERGENREZEPTOR-AGONISTS
Title (fr)
FORMES CRISTALLINES D'UN AGONISTE ARYLANILINE DU RÉCEPTEUR ADRÉNERGIQUE BÊTA-2
Publication
Application
Priority
- US 2004014302 W 20040507
- US 46881003 P 20030508
Abstract (en)
[origin: US2004224982A1] The invention provides crystalline solvate forms of a salt of a novel beta2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the solvate forms, formulations containing the pharmaceutical compositions, methods of using the solvate forms to treat diseases associated with beta2 adrenergic receptor activity, and processes useful for preparing such solvate forms.
IPC 8 full level
C07D 215/26 (2006.01); A61K 31/4704 (2006.01); A61P 11/06 (2006.01)
CPC (source: EP US)
A61P 11/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 215/26 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
LT LV
DOCDB simple family (publication)
US 2004224982 A1 20041111; US 7060712 B2 20060613; AT E450511 T1 20091215; DE 602004024383 D1 20100114; EP 1622875 A1 20060208; EP 1622875 B1 20091202; JP 2006528242 A 20061214; WO 2004101525 A1 20041125
DOCDB simple family (application)
US 84176104 A 20040507; AT 04751604 T 20040507; DE 602004024383 T 20040507; EP 04751604 A 20040507; JP 2006532854 A 20040507; US 2004014302 W 20040507